Abstract：
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing evidence is needed to ensure proper risk-benefit assessment and optimal utilization of this efficacious therapy. This review aims to provide a balanced perspective on the evidence-based cardiovascular and renal benefits of SGLT2is and the associated risk of GU infections. We also summarize and propose clinical practice considerations for SGLT2i-associated GU infections focusing on patients with cardiovascular disease.
摘要：
钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2is）已被证明可以减少2型糖尿病患者的不良心血管事件，全因死亡率,心力衰竭患者的心力衰竭住院治疗，以及不良的肾脏结局。然而,对泌尿生殖系统（GU）感染风险增加的担忧，尤其是尿路感染,仍然是他们更广泛采用的一个重大障碍。需要使用现有证据来解决这些误解，以确保正确的风险收益评估和这种有效疗法的最佳利用。这篇综述旨在为SGLT2is的基于证据的心血管和肾脏益处以及GU感染的相关风险提供一个平衡的观点。我们还总结并提出了针对心血管疾病患者的SGLT2i相关GU感染的临床实践注意事项。
